The Cooper Companies, Inc.

Equities

COO

US2166485019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 02:30:00 15/01/2026 am IST			5-day change	1st Jan Change
81.69 ^USD	-0.01%		-3.12%	-0.33%

15/01	The Cooper Companies, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 02:15 PM
09/01	Goldman Sachs Adjusts Price Target on Cooper to $73 From $71, Maintains Sell Rating	MT

Cooper Companies opens formal strategic review under pressure from Activist Investor

Esteban Tesson

Published on 12/05/2025 at 10:42 pm IST - Modified on 12/08/2025 at 12:37 pm IST

The Cooper Companies, Inc.

-0.01%

Cooper Companies opens formal strategic review under pressure from Activist Investor

The Cooper Companies announced on Thursday the launch of a formal strategic review aimed at identifying long-term value-creation levers for its shareholders. This initiative, arising amid growing activist investor pressure, was welcomed by the market, with the stock rising 8% during trading. The group aims to strengthen its competitiveness in its key markets, improve its operational efficiency, and optimize capital allocation.

The company, specializing in contact lenses through CooperVision and women's health products through CooperSurgical, has been targeted for several months by funds JANA Partners and Browning West. They are calling for governance reform and a more ambitious strategic direction. JANA Partners, which recently took a stake, welcomed the announcement as "an important first step to unlock Cooper's value potential."

Meanwhile, Cooper also issued encouraging guidance for FY 2026, estimatting EPS of between $4.45 and $4.60, above market expectations. Revenue is expected between $4.30bn and $4.34bn. The group also anticipates $50m in annual savings following a major restructuring completed in Q4, and announced that Colleen Jay will become chair of the board in January 2026.

Latest news about The Cooper Companies, Inc.

15/01	The Cooper Companies, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 02:15 PM
09/01	Goldman Sachs Adjusts Price Target on Cooper to $73 From $71, Maintains Sell Rating	MT
07/01	CooperVision to Launch Myday Misight 1 Day Myopia Control Soft Contact Lenses	CI
23/12	The Cooper Companies, Inc. Appoints Walter M Rosebrough, Jr. to its Board of Directors and Corporate Governance & Nominating Committee, Effective as of January 3, 2026	CI
23/12	Cooper Pick of the Week at Smart Insider Following Executives' Stock Purchases	MT
23/12	Coopercompanies appoints Walter M Rosebrough, Jr. to its board of directors	RE
13/12	The Cooper Companies, Inc. Announces Executive Changes	CI
09/12	Analyst recommendations: Colgate-Palmolive, Confluent, Draftkings, PepsiCo, Warner Bros…
08/12	BNP Paribas Exane Adjusts PT on Cooper Companies to $93 From $90, Maintains Outperform Rating	MT
08/12	Jefferies Adjusts Price Target on Cooper Companies to $100 From $85, Maintains Buy Rating	MT
06/12	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
05/12	Cooper Companies opens formal strategic review under pressure from Activist Investor
05/12	Barclays Adjusts Price Target on Cooper Companies to $91 From $85, Maintains Overweight Rating	MT
05/12	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
05/12	Sector Update: Health Care	MT
05/12	Citigroup Adjusts Cooper Price Target to $88 From $72, Maintains Neutral Rating	MT
05/12	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	MT
05/12	Piper Sandler Adjusts Price Target on Cooper Companies to $94 From $83, Maintains Overweight Rating	MT
05/12	Wells Fargo Adjusts Price Target on Cooper Companies to $82 From $72, Maintains Equalweight Rating	MT
05/12	JPMorgan Adjusts Price Target on Cooper Companies to $78 From $66, Maintains Neutral Rating	MT
05/12	Stifel Adjusts Price Target on Cooper Companies to $95 From $85, Maintains Buy Rating	MT
05/12	Goldman Sachs Adjusts Price Target on Cooper Companies to $71 From $64, Maintains Sell Rating	MT
05/12	Needham Adjusts Price Target on Cooper Companies to $100 From $94, Maintains Buy Rating	MT
05/12	Mizuho Adjusts Price Target on Cooper Companies to $100 From $85, Maintains Outperform Rating	MT
05/12	Baird Adjusts Price Target on Cooper Companies to $98 From $85, Maintains Outperform Rating	MT

Chart The Cooper Companies, Inc.

Duration

Period

COO: Dynamic Chart

Company Profile

The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVisionâs products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgicalâs portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.

Employees

15,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

26/02 - Q1 2026 Earnings Release (Projected)

More about the company